TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01684384

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Functional Respiratory Imaging
Description: HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
Study: NCT04749173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 432mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 144mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 144mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study: NCT03215212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear plug
Description: ear plug administered from 10 pm to 7 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear plug
Description: ear plug administered from 10 pm to 7 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear plug
Description: ear plug administered from 10 pm to 7 am
Study: NCT02962076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)
Description: this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
Study: NCT01748851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: capecitabine 1000mg/m2 bid po D1-D14
Study: NCT01900470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Goal Support
Description: IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
Study: NCT03653637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Life Force
Description: A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
Study: NCT01708694

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amylose
Description: One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amylopectin
Description: The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months.
Study: NCT05801094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: QL1604 3 mg/kg Q3W
Study: NCT02036034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forced air warmer (Bair Hugger)
Description: forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: warming blanket
Description: warming blanket placed on torso of patient under the drape.
Study: NCT00236938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer and stable erythropoietin (EPO) regimen
Description: Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stable erythropoietin (EPO) regimen
Description: Stable erythropoietin (EPO) dose and no supplemental iron.
Study: NCT00527813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position
Description: prone position for at least 16 hours per day
Study: NCT01270945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CV-18C3
Description: 3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT04652128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Subject will receive a single infusion of zoledronic acid 5mg/100mL intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive a single infusion of physiological saline 100mL intravenously.
Study: NCT02986204

Intervention type: PROCEDURE
Group type: OTHER
Intervention: removal of ENG implant
Description: the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~* questions about your medical/contraception history~* Review medical record~* physical examination~* urine sample for pregnancy test~Visit 2a - Radiology~* Have an ultrasound of your arm~* The radiologist will mark your arm at the location of the implant.~Visit 2b~* ultrasound of your arm to locate the implant. This is done by feeling the area.~* Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~* Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~* Provide a urine sample for pregnancy test~* Have the implant removal site examined

Intervention type: PROCEDURE
Group type: OTHER
Intervention: continuation of ING implant
Description: the researcher(s) will ask you to:~* To answer questions about your medical and contraception history~* Review your medical record~* Have a physical examination by the researcher~* Provide a urine sample for pregnancy test~* Have an ultrasound of your arm
Study: NCT01218997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral naltrexone 50 mg
Description: Tablet taken orally once daily for up to 1 year
Study: NCT04139590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panda

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panda

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Visual Analogue Scale - Original

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Visual Analogue Scale - Original
Study: NCT01752140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10-core prostate biopsy protocol
Description: Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vienna nomogram prostate biopsy protocol
Description: Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
Study: NCT03819231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution
Description: A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham mindfulness
Description: The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
Study: NCT01902485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of Contraceptive Initiation in Medical Abortion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of Contraceptive Initiation in Medical Abortion
Study: NCT02505126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tDCS
Description: One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
Study: NCT01500148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)
Description: A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
Study: NCT01731704

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiosurgery (SRS)
Study: NCT01212926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echographic analysis of myocardial deformation in 2D strain
Study: NCT01731704

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiation therapy (WBRT)
Description: External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
Study: NCT06045377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of Armolipid on Lipid Profile in Children With Hypercholesterolemia
Description: A prospective single center cohort study
Study: NCT01748851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: 5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
Study: NCT02400398

Intervention type: OTHER
Intervention: Tube feeding
Description: Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
Study: NCT04341727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: anti-rheumatic drug (DMARD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: anti-rheumatic drug (DMARD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Sulfate
Description: Antimalarial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Sulfate
Description: Antimalarial
Study: NCT01103076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyamide HD membrane
Description: Single use polyamide membrane
Study: NCT02418819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 3mg BID
Description: PF-06412562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 9mg BID
Description: PF-06412562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 45mg BID
Description: PF-06412562

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04095000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACE-TC SP
Description: The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
Study: NCT01611324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%
Description: 4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%
Description: 4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
Study: NCT02089750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthotics
Study: NCT01103076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyamide HD membrane
Description: Single use polyamide membrane
Study: NCT02089750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthotics

Intervention type: OTHER
Group type: OTHER
Intervention: Orthotics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthotics Plus Chiropractic Care
Description: The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).

Intervention type: OTHER
Group type: OTHER
Intervention: Wait List
Study: NCT01976845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol (20mg) 2 ml IV, in the pre-op area as a premedication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 2 ml IV, in the pre-op area as a premedication
Study: NCT03579199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exploration of abdominal cavity and liver using a NIR/ICG camera
Description: exploration of abdominal cavity and liver using a NIR/ICG camera
Study: NCT01863160

Intervention type: DRUG
Group type: OTHER
Intervention: 0.1% ZEP-3 cream
Description: Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream
Study: NCT04548882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso Knee System
Description: The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
Study: NCT04035720

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative risk
Description: Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative risk
Description: Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
Study: NCT00399334

Intervention type: DRUG
Intervention: antipsychotic medications
Description: as prescribed
Study: NCT01494311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch
Description: The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous injection of 0.5 ml Lidocain 1%
Description: After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of saline
Description: After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
Study: NCT00349492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IP
Description: irinotecan+cisplatin
Study: NCT02778581

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidic Blend 1
Description: daily intake of the content of one 45 mL bottle containing the product

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidic Blend 2
Description: daily intake of the content of one 45 mL bottle containing the product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily intake of the content of one 45 mL bottle containing olive oil
Study: NCT04688281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Medicurtain® 5ml prefilled syringe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GUARDIX-SG®
Description: GUARDIX-SG® 5ml prefilled syringe
Study: NCT00917813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD-247
Description: Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
Study: NCT01767792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance).
Study: NCT01976416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study: NCT03808948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFI
Description: The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.